NGM120 for Colorectal Cancer and Wasting Syndrome

This trial tests the drug NGM120 to determine its effectiveness for people with colorectal cancer who also experience cancer cachexia, a condition causing severe weight loss. The study assesses the effectiveness and safety of different NGM120 doses compared to a placebo. Participants will receive either a low or high dose of NGM120 or a placebo, administered every 4 or 8 weeks, assigned randomly. Ideal candidates for this trial have colorectal cancer and significant, unplanned weight loss due to cancer cachexia. As a Phase 2 trial, this research measures NGM120's effectiveness in an initial, smaller group, allowing participants to contribute to important treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that NGM120 is being tested for safety and effectiveness in people with colorectal cancer and cachexia, a condition characterized by severe weight loss and muscle wasting. In earlier studies, NGM120 was generally well-tolerated, with most patients not experiencing serious side effects. Common side effects included mild tiredness and nausea, which were manageable.

Researchers are excited about NGM120 because it offers a fresh approach to treating colorectal cancer and wasting syndrome. Unlike standard treatments like chemotherapy, which target rapidly dividing cells, NGM120 is designed to target specific pathways involved in cancer growth and metabolism. This potentially allows for more precise treatment with fewer side effects. Additionally, NGM120 is administered subcutaneously, which could be less invasive and more convenient compared to traditional intravenous chemotherapy. The possibility of using different dosing schedules, including high doses at extended intervals, offers flexibility that could enhance patient comfort and compliance.

Research has shown that NGM120 might help treat colorectal cancer and cancer cachexia, a condition causing severe weight loss. In an earlier study, all six patients assessed after 16 weeks managed to keep their disease under control. Four of these patients gained more than 5% of their body weight, and on average, muscle weight increased by 2.9%. The treatment was well tolerated, with no major side effects preventing its use. In this trial, participants will be assigned to different treatment arms, including various dosages and schedules of NGM120 or placebo. These early results suggest that NGM120 could help patients gain weight and muscle, which is important for managing cachexia.²³⁶⁷⁸